RxDoctor Payments Data

Vincent Verdi, MD

Ophthalmology · Norfolk, VANPI 1053326777

Payments from drug & device makers

$2,782in general payments, 2019–2025

Across 125 payments — averaging $22.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$630
  • Notal Vision, Inc.$433
  • Mallinckrodt Hospital Products Inc.$263
  • Sun Pharmaceutical Industries Inc.$257
  • Biotissue Holdings Inc.$180
  • Kala Pharmaceuticals, Inc.$155
  • plus $863 from 13 others

What the payments were for

  • Speaking & faculty fees$43316%
  • Food & beverage$2,23180%
  • Education$1184%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,782 in reported general payments places this provider in the 70th percentile of 509 ophthalmology providers in Virginia.

See all ophthalmology providers in Virginia

Medicare billing

Part B allowed, 2024
$1,050,104
Medicare patients
1,237
Services billed
6,962

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost97$55,714
RestasisCyclosporine41$46,939
CombiganBrimonidine Tartrate/Timolol70$25,474
XiidraLifitegrast16$24,799
Brimonidine Tartrate196$16,160
Alphagan PBrimonidine Tartrate32$15,043
Cyclosporine22$12,420
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol40$7,918
SimbrinzaBrinzolamide/Brimonidine Tart23$6,667
Travoprost32$5,172
RhopressaNetarsudil Mesylate13$4,678
Prednisolone Acetate97$3,860
Latanoprost385$3,455
Tobradex StTobramycin/Dexamethasone13$3,267
Ketorolac Tromethamine149$3,068

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan, Alphagan P$630$143,171240 claims
Bausch & Lomb Americas Inc.Xiidra$37$24,79916 claims
AlconSimbrinza$140$6,66723 claims
Aerie Pharmaceuticals, Inc.Rhopressa$97$4,67813 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$134$2,33714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 509 ophthalmology providers in Virginia.

Other ophthalmology in Norfolk

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →